Researchers from California State University San Marcos and The Scripps Research Institute have proposed a new neurobiological framework suggesting that the orexin system acts as a central coordinator linking sleep disturbance, chronic pain, and substance use disorder. Published in Frontiers in Neuroscience, this review synthesizes experimental evidence to argue that these three conditions, while traditionally studied in isolation, share common neurobiological mechanisms that may drive their frequent co-occurrence. The authors introduce the concept of maladaptive state allocation, a process in which the brain fails to properly prioritize behavioral responses to competing physiological demands, leading to a self-reinforcing cycle of pathology.
The orexin system, also known as the hypocretin system, consists of neuropeptides produced primarily in the lateral hypothalamus, dorsomedial hypothalamus, and perifornical area. These neurons project extensively throughout the central nervous system, influencing regions critical for arousal, motivation, emotional processing, stress regulation, and pain modulation. Key target areas include the locus coeruleus, ventral tegmental area, paraventricular nucleus of the thalamus, nucleus accumbens, amygdala, periaqueductal gray, and rostral ventromedial medulla. This widespread connectivity positions orexin as a state-integration network capable of dynamically regulating vigilance, salience attribution, and reward-seeking behavior under both physiological and pathological conditions.
Under normal physiological conditions, orexin transmission promotes adaptive behavioral prioritization by coordinating arousal, stress responsivity, nociception, and reward-seeking behaviors. However, the review proposes that chronic dysregulation of this system may result in maladaptive state allocation. This state is characterized by persistent hyperarousal, amplified pain-related salience, and excessive motivational value assigned to drug-associated cues. The authors argue that rather than functioning solely as a regulator of sleep or reward, orexin should be conceptualized as a distributed network that allocates behavioral resources according to physiological need, environmental context, and motivational significance.
Sleep disturbance is identified as a primary component of this triad, often conceptualized not merely as an inability to sleep but as a disorder of excessive physiological and cognitive arousal. Experimental evidence indicates that increases in orexin activity destabilize sleep architecture and produce insomnia-like phenotypes. Conversely, the effectiveness of dual orexin receptor antagonists, or DORAs, in treating insomnia supports the role of orexin-mediated arousal in sleep maintenance. These agents improve sleep by reducing orexin-driven arousal rather than directly promoting sleep, suggesting that persistent activation of orexin-dependent circuitry may contribute to pathological hyperarousal seen in chronic insomnia.
Chronic pain is framed within this model as a state of persistent salience, where nociceptive transmission becomes decoupled from its protective adaptive role. While orexin transmission in descending pain modulatory pathways generally produces antinociceptive effects, the review suggests that chronic engagement of orexin-responsive arousal and limbic networks may simultaneously increase vigilance toward pain-related signals. This parallel process may reinforce the behavioral significance of pain, creating a feedback loop where pain disrupts sleep and sleep loss, in turn, increases pain sensitivity and impairs endogenous pain inhibition. The bidirectional relationship between these two conditions highlights the potential for orexin-dependent circuits to mediate their reciprocal reinforcement.
Substance use disorder is described as a form of pathological incentive prioritization, where drug-related stimuli acquire disproportionate behavioral significance. Preclinical models demonstrate that orexin transmission contributes to drug seeking across multiple classes of abused substances, including cocaine, opioids, alcohol, nicotine, and methamphetamine. Pharmacological blockade of the orexin-1 receptor reduces cue-induced reinstatement and stress-induced relapse-like behavior, particularly under conditions requiring elevated motivation. This suggests that orexin is crucial for prioritizing behaviorally relevant goals, and its dysregulation may drive the compulsive drug seeking and relapse characteristic of addiction, especially when compounded by stress or sleep disruption.
The proposed triad model posits that sleep loss may increase pain sensitivity and craving, chronic pain may disrupt sleep and promote substance use, and repeated drug exposure may further destabilize sleep and pain regulation. This creates a self-reinforcing cycle where dysfunction in one domain increases vulnerability in the others. The authors emphasize that orexin transmission may act as a systems-level amplifier rather than an initiating cause, meaning that pathology in one area can propagate through shared orexin-dependent circuitry to affect the remaining conditions. This framework offers a mechanistic explanation for the high rates of comorbidity observed in clinical populations.
Individual differences in vulnerability to this triadic comorbidity may be influenced by biological sex, genetic factors, and stress exposure. For instance, chronic pain and insomnia are generally reported more frequently in females, while substance use disorders are diagnosed more commonly in males. Genetic variations affecting orexin transmission, as seen in narcolepsy type 1, demonstrate the critical role of this system in maintaining stable behavioral states. Additionally, the concept of orexin reserve, referring to the capacity of the system to recruit adaptive responses under demand, may explain why similar stressors produce markedly different behavioral outcomes across individuals.
Therapeutic implications of this framework point toward the potential of orexin-targeted therapies to address multiple components of the triad simultaneously. Dual orexin receptor antagonists, such as suvorexant, lemborexant, and daridorexant, are FDA-approved for insomnia and may indirectly reduce pain severity and vulnerability to substance use by improving sleep. However, clinical evidence for broader effects remains preliminary. A small crossover study found that suvorexant improved sleep and reduced experimental pain sensitivity in women with comorbid fibromyalgia and insomnia, but did not show significant improvements in self-reported clinical pain. Similarly, a study in individuals with opioid use disorder showed potential benefits for sleep and withdrawal symptoms, but was not designed to evaluate long-term relapse prevention.
Selective orexin-1 receptor antagonists represent another promising approach, as preclinical studies show they reduce cue-induced drug seeking and stress-induced reinstatement without consistently altering low-effort drug consumption. This selectivity may allow for the attenuation of pathological drug seeking while preserving adaptive functions of the orexin system. However, safety considerations are critical, as orexin-targeted therapies may have additive sedative effects when combined with other depressants, posing risks for patients with co-occurring substance use disorders. The net clinical effects may depend on the balance between reduced hyperarousal and the potential attenuation of endogenous pain-control mechanisms.
The review concludes that while substantial evidence links orexin to sleep, pain, and reward-related behaviors, direct evidence demonstrating orexin-mediated propagation across the full triad remains limited. The proposed framework is intended to generate testable predictions for future research, such as identifying biomarkers of orexin dysregulation that predict comorbid pathology or manipulating orexin transmission to alter pain and reward behaviors following sleep disruption. Longitudinal and translational studies assessing sleep, pain, and substance-related outcomes simultaneously will be essential for validating this model and developing personalized therapeutic strategies.
By viewing orexin through the lens of maladaptive state allocation, researchers may gain new insights into the neurobiological underpinnings of these highly comorbid conditions. This systems-level perspective moves beyond disorder-specific approaches, offering a unified framework for understanding how dysregulated behavioral prioritization contributes to the persistence of sleep disturbance, chronic pain, and substance use disorder. Future interventions may be optimized by considering how orexin-dependent mechanisms contribute to symptom expression across all three domains, potentially leading to more effective and integrated treatment strategies for patients suffering from multiple co-occurring conditions.
The review distinguishes between the established roles of orexin in specific physiological processes and the proposed interactions among the three conditions. While experimental evidence supports orexin’s involvement in arousal regulation, pain modulation, and reward-related behaviors, the central proposition that orexin-mediated dysregulation propagates pathology across these domains remains a hypothesis. The authors explicitly state that the framework is intended to generate testable predictions rather than serving as an established causal account. This distinction is critical for interpreting the model’s utility, as it relies on converging evidence from separate studies rather than direct experimental confirmation of cross-domain propagation. The framework suggests that dysfunction in one component may increase vulnerability to the others through shared circuitry, but this mechanism requires further empirical validation through longitudinal and translational studies that can assess sleep, pain, and substance-related outcomes simultaneously.
Specific neural circuits are highlighted as potential substrates for this integration, with the paraventricular nucleus of the thalamus identified as a particularly important node. This region receives dense orexin innervation and is thought to translate physiological and environmental signals into appropriate behavioral responses by interacting with cortical and limbic structures. The review notes that orexin neurons co-release glutamate and frequently co-express dynorphin, a neurochemical complexity that allows for the rapid initiation, sustained modulation, and constraint of behavioral responses. This mechanism may enable orexin neurons to coordinate multiple behavioral domains simultaneously while preventing excessive activation of downstream circuitry. The anatomical organization and projection diversity of the system suggest a role that extends beyond the regulation of any single behavior, positioning it as a distributed network that allocates behavioral resources according to physiological need and environmental context.
Future research directions outlined in the review include the identification of biomarkers for orexin dysregulation that might predict the development of comorbid pathology more accurately than measures from any individual disorder alone. The authors propose that manipulation of orexin transmission following sleep disruption should alter subsequent pain-related and reward-related behaviors beyond effects attributable to sleep loss itself. Additionally, individuals exhibiting evidence of orexin-related hyperarousal may demonstrate a greater likelihood of progressing from isolated symptoms to multi-domain pathology over time. These predictions provide a roadmap for experimental testing of the maladaptive state allocation framework. The review also emphasizes the need to determine whether specific orexin projections differentially regulate sleep, pain, and reward-related behaviors or whether common neural substrates underlie multiple components of the triad. Understanding these distinctions will be essential for developing personalized therapeutic strategies that target the dominant pathological processes within individual patients.
Subject of Research: Neurobiological framework linking sleep, pain, and addiction via orexin
Article Title: Maladaptive state allocation: an orexin-based framework linking sleep disturbance, chronic pain, and substance use disorder
Article References: Brunson, K. E., Bellitire, S. C., Kuper, S. D., Alcala, A. C. E., Martin-Fardon, R., & Flores-Ramirez, F. J. (2026). Maladaptive state allocation: an orexin-based framework linking sleep disturbance, chronic pain, and substance use disorder. Frontiers in Neuroscience, 20, Article 2003262. https://doi.org/10.3389/fnins.2026.2003262
Image Credits: AI Generated
DOI: 10.3389/fnins.2026.2003262
Keywords: orexin, hypocretin, sleep disturbance, chronic pain, substance use disorder, neurobiology, state allocation, comorbidity, Frontiers in Neuroscience, Maladaptive, state, allocation
News Source: Ophelia Keating. (November 10, 2026). Orexin system may link sleep, pain, and addiction. Scienmag.



